First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Siow Ming Lee, Christian Klaus Jochen Schulz, Kumar Prabhash et al. · The Lancet · 2023
Cited by 167 works. doi:10.1016/s0140-6736(23)00774-2
Authors
- Siow Ming Lee
- Christian Klaus Jochen Schulz
- Kumar Prabhash
- Dariusz Mirosław Kowalski
- Aleksandra Szczęsna
- Baohui Han
- Achim Rittmeyer
- Toby Talbot
- David Vicente
- Raffaele Califano
- Diego Luigi Cortinovis
- Dingzhi Huang
- Geoffrey Liu
- Federico Cappuzzo
- Jessica Reyes Contreras
- Martin Reck
- Ramón Palmero
- Milena Perez Mak
- Youyou Hu
References
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
- Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research